Member Info for HereforHemo

Mr I I’m pretty certain the interims will be out this week, maybe even tomorrow but if not certainly by Friday. I’m led to believe all product candidates will have updates and all are positive. We’ll wait and see what, if anything, that does to the SP.

No problem Chris. I’m expecting the interims out early next week and think the content to be positive. If I were to guess I’d say plenty of cash in the bank and really good progress on their three product candidates, CBR, CDX and HEMO CAR-T. Should be an exciting week..if I’m right.

Chris I have read all the documents pertaining to this and confirm both patent applications and fast tracking of IND approvals will be granted for successful applications. Under the guidelines I believe Hemogenyx would be initially awarded a grant of up to $4m to aid CBR going into clinical trials asap. Two rounds of approvals with the latter being in greater detail.

As a side note I think this is probably connected to why they have changed from one unnamed partner to another for CBR. The interims next week will hopefully tell us more. Exciting times.

More relevant to me is ‘HEMO to help achieve this goal’. Suppose it helps knowing the Governor of New York. Hopefully Kathy has put in a good word.

https://twitter.com/vmsandler/status/1570522646210838528?s=20&t=T8PVnwijwSxv0PoPLw8C5w

Micky I respect your opinion although I wouldn’t necessarily agree. Rather than speculate I’d wait for the interims being released which I’m sure will have positive updates on all three product candidates. Not too long to wait either. GLA

Mr India you are sadly mistaken if you think a financial update will cause the SP to rerate. It’s clear to me that with the CDX master cell line done with no update and Hemogenyx working with a different partner now on CBR, that the only meaningful update we’ll get is CAR-T IND application and approval. That could be soon or might be next year. Doubt you’ll last that long so you might as well get rid of some more now. If not, please try not to whine every day for the next 3 months.

Pumpky fair point well made.

There are certainly some people on here (that don’t need naming) who have clearly overstretched themselves that portray the two classic emotions that no investor should have, fear and greed. My advice to them is money is not worth destroying your mental health so take your losses and sell up. You’ll feel better in the long run not being involved in something you clearly cannot handle.
So onto the current situation with Hemogenyx. To me, SP aside it is looking extremely positive. For CBR, Hemogenyx had already put aside several million dollars to progress it and Vlads latest tweet inferred they’d be getting several million more in grants from the US government. It makes sense to me now why the governor of New York, Kathy Hochul toured Hemogenyx facilities last year, and why Vlad was so anti the Republican President. With $6-8m and a government backed fast track IND application this could be absolutely massive for Hemogenyx. In parallel we have the three manufacturing runs ongoing for HEMO CAR-T
in the lead up to IND application and clinical trials. Pre clinical results to date, facilities and staffing all point to the fact this unique treatment works on curing AML, and at over $400k a patient will be a major revenue earner down the line. With Hu-PHEC and the CDX antibody also in the pipeline I’m still of the view in the months ahead Hemogenyx will be many multiples of the current SP. I understand there’s a financial update on the way which will confirm there’s more than enough money in the bank to take them to being a clinical company so stay patient and hold and accumulate if you can, but if you’re struggling mentally do yourself a favour, sell up and don’t ever look at a share again. You’ll thank me for it down the road. GLA.

Mr. India So you complain no one is buying, not even the BOD, yet I’m the very same breath you’re quietly selling and forcing the price down. You my friend are a ****ing liar and a hypocrite. Sell the rest and move on!!

It’s relatively easy for people in the USA to trade HEMO on the LSE now. Be a good indication this week as to where they are up to. You would think some volume after his one to one meetings would indicate they’re in the manufacturing stage of CAR-T, whereas if we remain at this lowly level it would seem we’re looking towards the end of the year for IND and SP movement. Time will tell.

HK I think it’s because apart from patents, despite promising things over many years they’ve actually achieved nothing. Yes there is massive potential but that’s all it is at present. Look at CBR for example, two and a half years of work and not even progressed out of the lab yet, as far as we know. Other product candidates were promised to be in the clinic from 2018. CAR-T in 2021..2022..2023. Perhaps they should start under promising and over delivering..just a thought. Meanwhile the SP has tumbled from 14p to 1.4p. I’m sure many investors are at a loss too, a big one!

JHFH Think you are right. When the latest financials are released in a couple of weeks I expect a detailed update on all the product candidates to be released as well, if we don’t get them sooner. Then it’s onwards and upwards into Q4, IND application and planning for clinical trials. Worth the wait imo.

Pumpky As the share price has been destroyed and Vlad is ultimately responsible for it, you are correct in your statement. That being said we haven’t had any of our ‘imminent’ news yet. The fact is an update on progress with Selexis on CDX and CBR in vitro tests with their unnamed partner is long overdue. Manufacturing run updates for CAR-T could also come at any time. I’m confident on these as I believe CAR-T IND application will definitely be this year, most likely November but maybe December. There are around 14 business weeks left this year and a lot to be updated on. Vlad could well redeem himself with damage caused and could easily do so by Christmas. Personally I wouldn’t be seeing any shares now but each to their own.

I have no inside knowledge but from all that I see and all that I hear I am extremely confident. Everything I post is just my personal opinion.

Hulver It’s funny I was discussing that very point with a major shareholder in the early hours this morning. It’s fair to say that in the past Hemogenyx have been economical with the truth, after all there’s interviews with Vlad where he states CDX would be in the clinic in 2018 lol. That being said I prefer to look at the present and in particular why very experienced individuals have now decided to join Hemogenyx and why they have moved into a purpose built 10,000 square foot laboratory with clean rooms and commercial manufacturing capability. To me, and others may disagree, all things point to Hemogenyx becoming a clinical company, with a wholly owned product fully patent protected. It’s clear they have to get this right, there’s enough funds to do it with an SP at a level that there’s no ability to raise more capital, at least for 6-9 months. The latest recruits have stated they intend to ensure CAR-T becomes clinical and the science is ‘brilliant’. In my opinion I have no reason to disbelieve them and it’s now just a matter of time.

It’s my understanding things are going extremely well on all fronts. Anyone selling at this level will regret it in my opinion. Still, each to their own.

As I see it we’re getting a CDX update with Selexis any day, we’re getting the CBR in vitro results and probably the partner named any day and the first manufacturing run for CAR-T should be finished this week or next. Those results will send this skyward. Exciting month ahead!

I would agree with Mr India that it’s pointless buying as traders will only knock the price down and that it’s also a great time to buy and load up as you’re only going to buy at a higher price if you don’t lol.

#moodswings #sometimesbettertokeepquiet

‘I don’t mind’ that should say.